Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Phospholipid vesicles carry doxorubicin
What ifWhat if phospholipid vesicles carry the therapeutic agent?
Claim language“a polydopamine composition”
A phospholipid and cholesterol bilayer encloses an aqueous core containing doxorubicin. Intravenous infusion delivers the vesicles into circulation, and drug released from the vesicles inhibits topoisomerase II in exposed tumor cells.
1.1Fluorescent tracer marks the tumor
What ifWhat if the polydopamine particles carry only a diagnostic tracer?
Claim language“one or more therapeutic agents”
Polydopamine-coated silica particles contain a near-infrared fluorophore in the silica core. A fluorescence camera detects the marker in accessible tissue, and the radiation beam provides the treatment.
1.1Radiation precedes drug delivery
What ifWhat if the radiation course finishes before the polydopamine drug formulation is administered?
Claim language“and thereafter”
A linear accelerator delivers the prescribed fractions to the mapped tumor volume. After the final fraction, a polydopamine formulation delivers a cytotoxic drug to act on surviving tumor cells.
1.2Surgical excision removes the tumor
What ifWhat if surgical excision provides local tumor control after drug administration?
Claim language“administering radiation”
The surgeon uses preoperative imaging and intraoperative ultrasound to locate the lesion and guide resection. The excised tissue is oriented and examined to assess the surgical margins.
1.2Cryoprobes freeze the tumor
What ifWhat if percutaneous cryoablation provides local tumor control after drug administration?
Claim language“administering radiation”
Image guidance places hollow cryoprobes within the lesion, and expanding argon cools their tips during repeated freeze-thaw cycles. Computed tomography shows ice-ball growth relative to the lesion and adjacent structures.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Local delivery in veterinary oncology
A veterinary team places a sterile fibrin matrix containing drug-loaded polydopamine microparticles along the tumor bed after removal of a superficial tumor in a companion animal. The matrix holds the particles against the treated surface and releases the associated drug as fluid enters the matrix. A superficial X-ray applicator delivers the prescribed radiation after matrix placement.
Component substitution
Mesoporous silica as the drug carrier
Mesoporous silica microparticles replace polydopamine as the drug carrier in an injectable suspension. The particles are soaked in a solution of the therapeutic agent so that the agent enters the pores, then the free solution is removed and the particles are resuspended in a sterile vehicle. The suspension is administered before irradiation, and tissue fluid entering the pores carries the agent into the surrounding tissue.
Parameter or scale variation
One depot across five fractions
A single injectable depot contains drug-loaded polydopamine microparticles dispersed in a biodegradable hydrogel. In a bench model, the first of five radiation fractions starts 24 hours after depot placement, and the remaining four fractions follow at 24-hour intervals. Fluid samples collected immediately before each fraction are assayed for released drug to characterize exposure across the five-day schedule.
Combination with existing systems
Drug depot with catheter afterloading
Drug-loaded polydopamine is deposited in the tissue surrounding an array of interstitial brachytherapy catheters, leaving the catheter lumens clear. The external catheter ends connect through transfer tubes to a remote afterloader. After drug placement, the afterloader advances a sealed radioactive source through each catheter and holds it at programmed positions for specified durations before retracting it.
Drug delivery through an implanted port
A subcutaneous access port connects to a tunneled catheter with its outlet in the treatment cavity. Before each scheduled administration, an operator accesses the port with a noncoring needle, injects the polydopamine drug suspension and flushes the catheter with a compatible sterile vehicle. Radiation follows delivery through the catheter, and the port remains in place for subsequent administrations.
Automated or data-driven variant
Software verifies infusion before irradiation
A programmable syringe pump administers the polydopamine drug suspension and sends the delivered volume, completion timestamp and alarm state to a treatment workflow application. The application compares the reported volume with the prescribed volume and checks whether the configured post-infusion interval has elapsed. It marks the radiation session ready for operator review after both checks pass and the pump reports no active alarm.
Specific version of a part
Doxorubicin adsorbs onto polydopamine
Doxorubicin adsorbs to polydopamine nanoparticles through interactions between aromatic groups. The loaded particles are dispersed in sterile saline for injection into the tumor before irradiation.
Coated liposomes carry irinotecan
A phospholipid vesicle encloses irinotecan in its aqueous core and carries a polydopamine coating on its outer surface. The vesicles are suspended in an isotonic vehicle for intravenous administration before irradiation.
Shaped photon beams deliver fractions
A linear accelerator delivers megavoltage photon beams after administration of the polydopamine formulation. A multileaf collimator shapes the beam at each angle, and cone-beam computed tomography verifies patient alignment before each fraction.
A stepped source delivers brachytherapy
After drug administration, an applicator positions a source channel in or near the tumor. A remote afterloader steps a sealed iridium-192 source through programmed positions and controls the dwell time at each position.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1administering to a subject in need thereof a polydopamine composition comprising one or more therapeutic agents; and thereafter
The oxygen microbubbles stabilized with polydopamine nanoparticles have excellent biocompatibility, can realize rapid and efficient delivery of oxygen, and thus have an important application value in the field of highly-efficient intravenous oxygen supply.
B · US 2022/0105034 A1 · abstract
1.2administering radiation to the patient.
The ionizing radiation source applies a radiation dose between the axially spaced apart balloons while the infusion lumen releases the radiosensitizer therein.
A · US 2005/0124844 A1 · ¶ 25
An empty cell means only that no passage was reproduced there.
Statements in these documents
A particularly common disadvantage with PTA and other known procedures for opening stenotic regions is the frequent occurrence of restenosis.
A · US 2005/0124844 A1 · ¶ 4
More particularly, the present invention relates to combination radiation and radiosensitizer delivery devices for inhibiting hyperplasia following balloon angioplasty and other interventional treatments.
A · US 2005/0124844 A1 · ¶ 3
Therefore, it is still an urgent problem to prepare a biocompatible, stable and dispersed microbubble system and realize efficient intravenous oxygen supply.
B · US 2022/0105034 A1 · ¶ 3
The microbubble dispersion system has good dispersibility and stability in water, can realize rapid and efficient delivery of oxygen, and thus has an important application value in the field of highly-efficient intravenous oxygen supply.
B · US 2022/0105034 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355359 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355359/, SHA-256 412f445a0061a49c2ea0637c1fb2319cfed62d245d552d18b5ecedc25ef2316a